Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Somewhat Bullish +50

Intuitive Surgical Shareholders Approve All Proposals at 2026 Annual Meeting, Elect 10 Directors

📈 Intuitive Surgical shareholders voted to approve all four proposals at the 2026 Annual Meeting, including the election of 10 directors.

💼 The board slate re-elected for service until the 2027 meeting consists of Dr. Craig Barratt, Joseph Beery, Lewis Chew, Dr. Gary Guthart, Sreelakshmi Kolli, Dr. Amy Ladd, Keith Leonard, Jami Dover Nachtsheim, Dr. Monica Reed, and David Rosa.

💰 Executive compensation packages for named executive officers were approved by advisory vote of the stockholders.

📋 Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

🔧 The meeting also approved an amendment and restatement of the company's 2010 Incentive Award Plan.

💵 Intuitive Surgical reported full-year 2025 revenue exceeding $10 billion with total procedure growth of 19%.

🤖 CEO David Rosa highlighted strong adoption of the da Vinci 5 system and rapid growth in single-port (SP) and Ion bronchoscopic platforms.

🔬 The company secured 510(k) clearance for Force Feedback instruments as part of its ongoing innovation roadmap.

🌍 Global international exposure grew significantly from 17% of patients treated in 2005 to 35% by 2025.

💊 Revenue for Q1 2026 reached approximately $2.77 billion, representing a 23% year-over-year increase.

⚠️ Management noted challenges including competitive pricing in China and budget pressures in Japan and the U.K.

📉 The company faces continued pressure in the bariatric market in the U.S. and internationally due to GLP-1 drug usage.

⭐ Intuitive's technology has impacted over 20 million patients, with the platform receiving a world-class J.D. Power Net Promoter Score of 76 in 2025.

📄 Gary Loeb stated that final vote results will be reported in a Form 8-K filed with the SEC within four business days.

🤖 The company maintains a multi-year digital and AI roadmap alongside its robotics and advanced vision systems mission.

Bullish Signals
  • Intuitive Surgical shareholders approved all four proposals at the 2026 Annual Meeting, including the re-election of the full board slate of 10 directors, demonstrating strong confidence in management's leadership.
  • The company reported robust financial performance with 2025 revenue exceeding $10 billion and Q1 2026 revenue reaching roughly $2.77 billion, representing a 23% year-over-year increase.
  • Total procedure growth accelerated to 19% in 2025, with Q1 2026 showing a 17% year-over-year increase, driven by broad adoption of the da Vinci 5 platform and rapid growth in SP and Ion segments.
  • The global installed base expanded significantly during this period, adding roughly 1,900 systems in 2025 to reach approximately 12,000 total systems worldwide.
  • Management highlighted major technological milestones including the receipt of 510(k) clearance for Force Feedback instruments and a strategic multi-year digital/AI roadmap to drive future innovation.
  • Customer satisfaction remains at world-class levels with a J.D. Power 2025 Net Promoter Score of 76, significantly above the 70 threshold considered excellent in the industry.
  • International expansion continues its upward trajectory, with the proportion of patients treated outside the U.S. rising to 35% by 2025 from 17% in 2005.
  • The company maintains strong scientific and clinical standing, evidenced by over 4,800 cumulative peer-reviewed articles published on its products as of 2025.
Risk Factors
  • CEO David Rosa explicitly cited external headwinds as significant challenges for the company in 2026, including a dynamic trade environment, increased pricing and competition in China, government budget pressures in Japan and the U.K., and continued pressure in the bariatric market tied to GLP-1 drugs.
  • The stock is currently experiencing a sell-off, with analysts suggesting it has set up a '30% rebound opportunity,' indicating recent downward momentum and negative sentiment despite strong operating results.
  • Management emphasized increased R&D for 2026, which could lead to elevated capital expenditures that may pressure near-term profitability margins given the high absolute revenue of over $10 billion.
  • The company faces ongoing government budget pressures in key international markets like Japan and the U.K., which directly threatens future demand and growth trajectories in those regions.
Full Analysis
Intuitive Surgical shareholders have unanimously approved all four proposals at the company's 2026 Annual Meeting of Stockholders, held virtually on April 30, 2026, and elected a slate of 10 directors to serve until the 2027 annual meeting. The approved initiatives included an advisory vote on executive compensation, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and the approval of an amendment to the company's 2010 Incentive Award Plan. Gary Loeb, Executive Vice President and Chief Legal and Compliance Officer, confirmed the presence of a quorum based on proxies received among 355,230,371 outstanding shares of common stock as of the March 2, 2026 record date, with preliminary vote reports indicating sufficient votes for each nominee. CEO David Rosa highlighted the company's robust operational performance and strategic focus on global expansion and technological innovation during his presentation following the meeting. Intuitive Surgical reported 2025 revenue just over $10 billion, representing a 19% total procedure growth, with a global installed base reaching approximately 12,000 systems after the placement of roughly 1,900 new systems in 2025. The company's first quarter of 2026 saw revenue of about $2.77 billion, marking a 23% increase year over year, alongside 17% total procedure growth. Rosa emphasized the broad adoption of the da Vinci 5 platform, rapid growth for the single-port (SP) and Ion platforms, and recent 510(k) clearance for Force Feedback instruments, all underpinned by a multi-year digital and artificial intelligence roadmap. Management outlined the company's mission through the "Quintuple Aim," which focuses on improving patient outcomes, enhancing patient experience, optimizing care team experiences, lowering total cost of care, and expanding access to minimally invasive surgery globally. Rosa noted that Intuitive's technology has impacted more than 20 million patients in its history, with international procedures rising from about 17% of the total in 2005 to 35% by 2025, a trajectory expected to continue. The board includes Dr. Craig Barratt, Joseph Beery, Lewis Chew, Dr. Gary Guthart, Sreelakshmi Kolli, Dr. Amy Ladd, Keith Leonard, Jami Dover Nachtsheim, Dr. Monica Reed, and David Rosa, with Amal Johnson's tenure ending after 16 years as an exemplary board member who previously chaired the compensation committee. Despite challenges such as dynamic trade conditions, pricing competition in China, government budget pressures in Japan and the U.K., and GLP-1 drug pressure in the bariatric market, the company maintained a world-class customer sentiment with a Net Promoter Score of 76 based on a third-party J.D. Power survey.